Xenon Pharmaceuticals Inc.
XENE
$58.76
-$0.79-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -409.20M | -383.17M | -345.91M | -306.33M | -278.23M |
| Total Depreciation and Amortization | 2.40M | 2.47M | 2.54M | 2.60M | 2.62M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.30M | 61.16M | 59.89M | 53.23M | 53.37M |
| Change in Net Operating Assets | 12.98M | 13.17M | 4.36M | -1.52M | -7.71M |
| Cash from Operations | -337.52M | -306.36M | -279.12M | -252.02M | -229.94M |
| Capital Expenditure | -1.01M | -889.00K | -799.00K | -1.26M | -1.57M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -636.29M | -222.91M | 218.80M | 255.07M | 217.34M |
| Cash from Investing | -637.29M | -223.79M | 218.00M | 253.80M | 215.77M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 958.94M | 958.98M | 117.11M | 15.71M | 13.35M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 958.94M | 958.98M | 117.11M | 15.71M | 13.35M |
| Foreign Exchange rate Adjustments | 22.00K | 392.00K | 458.00K | -595.00K | -535.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.85M | 429.21M | 56.45M | 16.89M | -1.35M |